Accendra Health, the December 2025 rebrand of Owens & Minor following the $375 million sale of the legacy Products & Healthcare Services distribution arm, closed the second quarter of fiscal 2026 with a 10.1% revenue decline, $89.1 million of GAAP net loss from continuing operations, and a $36.5 million year-over-year drop in adjusted EBITDA to $60.1 million, a quarter dominated by the loss of a large commercial payor contract, $17.3 million of debt-modification charges from the Balance Sheet Optimization Transaction, and a $25.8 million exit and realignment charge linked to the same payor exit. The most important structural signal in the print is not the loss itself but the June refinancing, which exchanged $1.03 billion of 9.000%–9.750% unsecured notes due 2029 and 2030 for $1.24 billion of 9.000%–9.750% secured notes due 2032 and 2033, cut total funded debt by $370 million to $1.75 billion, extended weighted-average debt life from 2.7 to 5.5 years, and captured $115 million of discount at issuance.
Against that backdrop, the equity is trading at roughly $73 million of market capitalization on 76.9 million shares at $0.951, against $1.71 billion of net debt and a $1.23 billion goodwill line that reflects the legacy Owens & Minor acquisition history; the market is now pricing the Patient Direct business as if it were a single-asset turnaround with high yield-style debt overhang and a departing CEO, not as a healthcare-services platform. The board adopted a Section 382 Tax Asset Preservation Plan on August 10 with a 4.9% beneficial-ownership trigger and a three-year final expiration in August 2029, a defensive mechanism to protect the company's net operating losses ahead of what the bull case argues is a multi-year operating-margin recovery. President and CEO Edward A. Pesicka notified the board on August 10 of his intention to retire by year-end, and the market is now waiting for a successor capable of executing the post-P&HS reset.
The next data points that test this thesis are the Q3 2026 print in early November, the announcement of a permanent CEO, the early read on whether the Sleep Center of Excellence nationwide rollout and the new commercial payor contracts called out by management convert into revenue, and the cash balance at September 30 - a metric that matters more than usual because operating cash use was $26.0 million in Q2 and free cash flow was negative $25.1 million, against only $7.7 million of cash on the balance sheet at June 30.